Side Effects of deucravacitinib: A Synthesis of Findings from 3 Studies

  1. Home
  2. Side Effects of deucravacitinib
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Side Effects of deucravacitinib: A Synthesis of Findings from 3 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Side Effects of deucravacitinib: A Synthesis of Findings from 3 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Deucravacitinib is an oral, selective, allosteric tyrosine kinase 2 inhibitor that blocks cytokine signaling involved in psoriasis pathogenesis. 3 . Deucravacitinib is a promising new oral small molecule that selectively inhibits tyrosine kinase 2 (TYK2) for the treatment of psoriatic arthritis (PsA). 1 . Deucravacitinib has high functional selectivity for TYK2 versus the closely related Janus kinases (JAKs) 1/2/3. 2 .

Reasons for Side Effects

Deucravacitinib works by inhibiting a protein called TYK2, which plays a role in the activation of immune cells. Inhibiting TYK2 helps to reduce inflammation and improve symptoms of inflammatory diseases like psoriasis and psoriatic arthritis. However, TYK2 is also important for other cells in the body, so inhibiting it can lead to side effects.

Common Side Effects

Upper Respiratory Tract Infection

Upper respiratory tract infection was reported as a side effect of deucravacitinib. 3 .

Headache

Headache was reported as a side effect of deucravacitinib. 3 .

Abdominal Pain

Abdominal pain was reported as a side effect of deucravacitinib. 3 .

Dyspepsia

Dyspepsia was reported as a side effect of deucravacitinib. 3 .

Fatigue

Fatigue was reported as a side effect of deucravacitinib. 3 .

Rash

Rash was reported as a side effect of deucravacitinib. 3 .

Elevated Liver Enzymes

Elevated liver enzymes were reported as a side effect of deucravacitinib. 3 .

Side Effects Management

Upper Respiratory Tract Infection

If you experience symptoms of an upper respiratory tract infection, consult your doctor.

Headache

If you experience severe headaches, consult your doctor.

Abdominal Pain

If you experience severe abdominal pain, consult your doctor.

Dyspepsia

If you experience severe dyspepsia, consult your doctor.

Fatigue

If you experience severe fatigue, consult your doctor.

Rash

If you experience severe rash, consult your doctor.

Elevated Liver Enzymes

If elevated liver enzymes are detected, follow your doctor's instructions.

Comparison Between Studies

Commonalities

Three studies have shown that deucravacitinib is a promising new oral small molecule for the treatment of psoriasis and psoriatic arthritis. 3 1 2 .

Differences

The pharmacokinetics and safety of deucravacitinib were evaluated in a study of healthy Chinese subjects. 3 . The efficacy and safety of deucravacitinib for psoriatic arthritis were evaluated in a Phase II clinical trial. 1 . The kinase specificity of deucravacitinib was compared to JAK 1/2/3 inhibitors. 2 .

Real-World Applications: Precautions

Deucravacitinib is a promising drug for treating psoriasis and psoriatic arthritis, but it carries the risk of side effects. If you are considering taking deucravacitinib, it is important to consult your doctor and choose a treatment plan that is right for you.

Limitations of Current Research

There is a lack of research evaluating the long-term efficacy and safety of deucravacitinib.

Future Research Directions

Research is needed to evaluate the long-term efficacy and safety of deucravacitinib.

Conclusion

Deucravacitinib is a promising new oral small molecule for treating psoriasis and psoriatic arthritis. 3 1 2 . However, it also carries the risk of side effects. If you are considering taking deucravacitinib, it is important to consult your doctor and choose a treatment plan that is right for you.

Keywords
Benefit Keywords
PsA treatment
1
Psoriasis
TYK2 inhibition
2
Risk Keywords
Literature analysis of 3 papers
Positive Content
3
Neutral Content
0
Negative Content
0
Article Type
0
0
0
1
3
1.

Deucravacitinib for the treatment of psoriatic arthritis: the evidence so far.

Author: MartinsAna, LéAna Maria, TorresTiago

PsA treatment

This article reviews the current knowledge on deucravacitinib, a new oral small molecule that selectively inhibits tyrosine kinase 2 (TYK2), for the treatment of PsA. TYK2 is responsible for mediating intracellular signalling of cytokines involved in the pathogenesis of PsA and psoriasis.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

2.

Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors.

Author: ChimalakondaAnjaneya, BurkeJames, ChengLihong, CatlettIan, TagenMichael, ZhaoQihong, PatelAditya, ShenJun, GirgisIhab G, BanerjeeSubhashis, ThroupJohn

Psoriasis
TYK2 inhibition

Deucravacitinib, a TYK2 inhibitor, shows high selectivity for TYK2 compared to JAK 1/2/3 inhibitors, demonstrating its potential as a safe and effective treatment for psoriasis.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.